/Companies

Pasithea Therapeutics

NASDAQ: KTTA

Venice, US · Founded 2020 · Delaware corporation · 2 known investors

Find your way into Pasithea Therapeutics

90 people in our graph share verified history with the Pasithea Therapeutics team — schools, employers, funds. One of them is your warm intro.

Martina de Majounlockedknows Tiago Reis Marques · together at Institute of Psychiatry (at the Maudsley), King´s College (overlapped)
knows the team · via Institute of Psychiatry (at the Maudsley), King´s College
knows the team · via Pasithea Therapeutics
×6knows the team · via Universidade de Coimbra
×3knows the team · via King's College London

Pasithea is a biotechnology company focused on the discovery and development of therapeutics for central nervous system disorders and RASopathies. Its research targets conditions including Neurofibromatosis type 1 (NF1), ALS, multiple sclerosis, and schizophrenia.

Founders & leadership

Pasithea Therapeutics was founded in 2020 by Lawrence Steinman and Tiago Reis Marques.

LSLawrence Steinman
Lawrence SteinmanCo-founder
TRTiago Reis Marques
Tiago Reis MarquesCo-founder · Chief Executive OfficerTiago Reis Marques is a psychiatrist and neuroscience researcher with over 15 years of experience in psychiatric disorders, serving as CEO of Pasithea Therapeutics; he holds positions as a senior fellow at Imperial College London and clinical lecturer at King's College London's Institute of Psychiatry, Psychology & Neuroscience, and has conducted research using PET and MRI imaging to identify neurobiological treatment targets for mental illness.
IM
Israel Maxx AbramowitzNamed on SEC filing
CA
Craig AuringerNamed on SEC filing

Investors · 2

Reported raises · per SEC filings

Form D private placements

$31.8M disclosed across 3 of 4 rounds · 2020–2025

▶$30.4MraisedDec 2021 · 21 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Lawrence SteinmanDirector
  • Simon DumesnilDirector
  • Stanley M. GlossExecutive Officer
  • Emer LeahyDirector
  • Tiago Andre Dos Reis MarquesExecutive Officer, Director
  • Yassine BendiabdallahExecutive Officer, Director
Offering amount
$30.4M
Amount sold
$30.4M
Sales commissions
$2.7M
Placement agents
EF Hutton, division of Benchmark Investments, LLC
First sale
Nov 2021
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.2MraisedMar 2021 · 30 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Lawrence SteinmanDirector
  • Tiago Reis MarquesDirector
  • Israel Maxx AbramowitzExecutive Officer, Director
  • Craig AuringerExecutive Officer, Director
Offering amount
$5M
Amount sold
$1.2M
First sale
Jan 2021
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$250KraisedJan 2021 · 1 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Lawrence SteinmanDirector
  • Tiago Reis MarquesDirector
  • Israel Maxx AbramowitzExecutive Officer, Director
  • Craig AuringerExecutive Officer, Director
Offering amount
$1M
Amount sold
$250K
First sale
Nov 2020
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$65.3Mvaluation at IPOSep 2021 · $5.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Competitors · 4

by search overlap

Companies competing with Pasithea Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Frequently asked questions

What does Pasithea Therapeutics do?
Pasithea is a biotechnology company focused on the discovery and development of therapeutics for central nervous system disorders and RASopathies. Its research targets conditions including Neurofibromatosis type 1 (NF1), ALS, multiple sclerosis, and schizophrenia.
Who founded Pasithea Therapeutics?
Pasithea Therapeutics was founded by Lawrence Steinman, Tiago Reis Marques in 2020.
Who are Pasithea Therapeutics's investors?
Pasithea Therapeutics's investors include Vivo Capital, Janus Henderson Investors.
How much funding has Pasithea Therapeutics raised?
Pasithea Therapeutics has disclosed $31.8M raised across 3 of its 4 known rounds.
Where is Pasithea Therapeutics headquartered?
Pasithea Therapeutics is headquartered in Venice, US.